Major Pipeline


The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China (as of February 2024).

XTANDI and Strategic products

XTANDI and Strategic products

 

Projects with Focus Area Approach

Projects with Focus Area Approach

 

Others

Others

 

Rx+® Program

Rx+® Program

 

Reference Materials

Please click IR Library: Overview of R&D Pipeline for more detailed information.

 

Related Links